# A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Chronic Hepatitis C (CHC) Patients With Compensated Liver Cirrhosis (LC)

> **NCT00304551** · PHASE3 · COMPLETED · sponsor: **Chugai Pharmaceutical** · enrollment: 180 (estimated)

## Conditions studied

- Liver Cirrhosis
- Chronic Hepatitis C

## Interventions

- **DRUG:** peginterferon alfa-2a 180μg
- **DRUG:** peginterferon alfa-2a 90μg
- **DRUG:** ribavirin

## Key facts

- **NCT ID:** NCT00304551
- **Lead sponsor:** Chugai Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2009-12
- **Final completion:** 2010-06
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2010-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00304551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00304551, "A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Chronic Hepatitis C (CHC) Patients With Compensated Liver Cirrhosis (LC)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00304551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*